Methylphenidate ER

The Defense Logistics Agency is preparing to issue a national requirements contract for Methylphenidate ER Tablets in 18MG, 27MG, 36MG, and 54MG strengths, packaged in 100-count bottles. This procurement will be conducted as an unrestricted, fully competitive acquisition under FAR Part 12 as a commercial item, using a firm-fixed-price, requirements-type contract structure with a one-year base period and four one-year option periods. The resulting contract will serve as the national supply source for Methylphenidate ER Tablets, supplying the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons through the DLA and VA prime vendor programs. Annual usage estimates will be specified in the solicitation’s schedule, and all eligible sources may submit proposals. The contract is designed to ensure consistent, nationwide availability of this critical medication. The solicitation, numbered SPE2D226R0013, is currently in the pre-solicitation phase with a projected release date in September 2026, though the agency retains the right to issue it earlier or later. The contract will be posted on both the DLA Bid Board System and SAM.gov, and interested parties are encouraged to monitor these sites and set up automated notifications for updates. All correspondence should be directed to Jeremy Brown at jeremy.brown@dla.mil or (445) 737-5419, with Jason Wray available as a secondary point of contact. The acquisition is managed by DLA Troop Support, headquartered in Philadelphia, Pennsylvania, and is classified under NAICS code 325412 for pharmaceutical preparation manufacturing.